内科

目的探讨尿激酶联合奥扎格雷钠治疗80岁以上高龄急性脑梗死患者的临床疗效及安全性。方法选取2014年1月至2017年12月我院收治的80岁以上高龄急性脑梗死患者66例为研究对象，根据患者及家属意愿将纳入研究的老年患者分为溶栓治疗组（36例）和非溶栓治疗组（30例），采用随机数字表法将溶栓治疗组患者随机分为联合溶栓组（18例）和尿激酶溶栓组（18例）。联合溶栓组患者采用尿激酶联合奥扎格雷钠治疗，尿激酶溶栓组患者采用尿激酶治疗，非溶栓治疗组患者采用奥扎格雷钠治疗。比较三组患者治疗24 h、3 d、7 d后的卒中量表(NIHSS)评分；比较三组患者治疗7 d的出血事件发生率和病死率。结果治疗方法与治疗时间对三组患者NIHSS评分的影响存在差异（P＜0.05）；治疗方法与治疗时间之间无交互作用（P＞0.05）。治疗7 d后，三组患者的治疗有效率、显效率比较差异有统计学意义，表现为联合溶栓组＞尿激酶溶栓组＞非溶栓治疗组；联合溶栓组患者的显效率显著高于非溶栓治疗组，差异有统计学意义（P＜0.05）。治疗7 d，三组患者的出血事件发生率及病死率比较，差异无统计学意义（P＞0.05）。结论尿激酶联合奥扎格雷钠治疗80岁以上高龄急性脑梗死患者早期临床疗效显著，不会增加患者出血及死亡风险。

ObjectiveTo investigate the clinical efficacy and safety of urokinase combined with sodium ozagrel in the treatment of elderly patients with acute cerebral infarction over 80 years old. Methods66 patients with acute cerebral infarction over 80 years old admitted in our hospital from January 2014 to December 2017 were selected as subjects. All subjects enrolled in the study were divided into thrombolytic therapy group (36 cases) and non-thrombolytic therapy group (30 cases) according to voluntary principle. Patients in the thrombolytic group were divided into combined thrombolytic group (18 cases) and urokinase thrombolytic group (18 cases) according to random number table method. Combined thrombolysis group were given urokinase combined with sodium ozagrel, urokinase thrombolytic group were treated with urokinase, and non-thrombolytic group were treated with sodium ozagrel. The National Institutes of Health Stroke Scale (NIHSS) score of the three groups were compared after 24 h, 3 d, 7 d of treatment. The incidence of hemorrhagic events and mortality in the three groups were compared. ResultsThe effects of therapy and therapeutic time on NIHSS score in the three groups were significantly difference (P＜0.05). There was no interaction between therapy and therapeutic time (P＞0.05). After 7d of treatment, the difference of effective rate and markedly effective rate in the three groups were statistically significant, the combined thrombolytic group＞urokinase thrombolytic group＞non-thrombolytic group. The markedly effective rate of combined thrombolytic group was significantly higher than non-thrombolytic group, the difference was statistically significant (P＜0.05). There was no significant difference in the incidence of hemorrhagic events and mortality between the three groups (P＞0.05). ConclusionThe clinical efficacy of urokinase combined with sodium ozagrel in the treatment of patients with acute cerebral infarction over 80 years old is effective and safety, and it will not increase the risk of cerebral hemorrhage and death.